MeiraGTx Holdings plc — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 11, 2021. MeiraGTx is a clinical-stage gene therapy company with six programs in clinical development and additional preclinical programs. It had no approved products and generated no product-sales revenue.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| License revenue from Janssen | $15.6 million | $13.3 million |
| Research and development expense, net | $33.9 million | $24.9 million |
| General and administrative expense | $44.2 million | $46.7 million |
| Total operating expenses | $78.1 million | $71.6 million |
| Operating loss | $62.6 million | $58.3 million |
| Net loss | $58.0 million | $54.7 million |
| Basic and diluted loss per share | $1.54 | $1.65 |
License revenue reflects amortization of Janssen’s $100 million 2019 upfront payment, not product sales. Janssen research reimbursements are generally recorded as offsets to R&D expense. Gross R&D spending rose to $96.6 million from $65.0 million, with the increase partly offset by higher Janssen reimbursements. There is no meaningful product gross margin reported.
- Cash and cash equivalents: $209.5 million at year-end, versus $227.2 million in 2019. The company also reported $38.5 million in Janssen receivables, expected in Q1 2021.
- Cash flow: $64.0 million used in operating activities, versus $20.0 million provided in 2019, when the $100 million Janssen upfront payment supported operating cash flow. Investing used $37.0 million; financing provided $82.7 million.
- Liquidity: Current assets of $272.6 million and current liabilities of $54.1 million, implying working capital of about $218.4 million. Management estimated available cash and expected Janssen research funding and milestone payments could fund operations and capital needs into mid-2023; this estimate depends on assumptions and is not assured.
- Debt and obligations: The company reported no debt outstanding. Lease obligations totaled about $22.2 million, of which $2.6 million was current. Total liabilities were $125.1 million and shareholders’ equity was $238.6 million.
Changes versus 2019
- Net loss increased by $3.2 million as total operating expenses grew faster than license revenue.
- Net R&D expense increased $9.0 million, reflecting expanded clinical-material manufacturing, payroll, acquired research and development, facilities and depreciation. Gross R&D expense rose $31.6 million, with Janssen reimbursements increasing $29.3 million.
- G&A expense declined $2.5 million, primarily due to lower payroll-related costs and travel, partly offset by higher insurance, share-based compensation and rent.
- Operating cash flow shifted from a $20.0 million inflow to a $64.0 million outflow. Cash balances declined despite $82.7 million of financing proceeds, including public and at-the-market share offerings.
Outlook, commentary and risks
- Management anticipated a Phase 3 Lumeos trial of AAV-RPGR and a Phase 3 AAV-RPE65 trial in 2021, and an AAV-GAD IND filing by Q3 2021. These are forward-looking plans, not assured outcomes.
- Reported interim AAV-RPGR results included statistically significant retinal-sensitivity improvement at low and intermediate doses; six of seven patients had improved or stable treated-eye vision at 12 months. AAV-AQP1’s first three-patient cohort was described as well tolerated, with encouraging symptom and salivary-output responses; the sample and follow-up were limited.
- In January 2021, the company completed the acquisition of manufacturing facilities in Shannon, Ireland. The plasmid and DNA facility was complete, while the viral-vector facility was expected to be completed by year-end 2021. Startup, scale-up, regulatory compliance and supply capacity remain execution risks.
- Janssen has exclusive global commercialization rights to AAV-RPGR, AAV-CNGB3 and AAV-CNGA3; it funds specified costs and the company is eligible for milestones and royalties. Payments and future revenue depend on development and commercial performance.
- Key risks include continuing losses and need for future capital; uncertain clinical and regulatory outcomes; dependence on leading candidates and collaborators; manufacturing and supply constraints; competition and reimbursement uncertainty; and COVID-19-related trial, staffing and supply disruptions. The company reported some trial delays and limited supply-chain disruption. It stated the pandemic had not materially affected FY2020 results, but future impact was uncertain.
- Unusual items included a $7.7 million noncash R&D charge for acquired Emrys in-process research and development and $18.4 million of share-based compensation. No material legal proceedings were reported. The financial statements received an unqualified audit opinion; management reported effective financial-reporting controls, with no auditor attestation because the company was an emerging growth company.
Investor verification priorities
- Check actual enrollment, trial design, safety and full follow-up data for the planned AAV-RPGR and AAV-RPE65 pivotal programs, and progress on the AAV-GAD IND.
- Verify the timing and receipt of Janssen receivables, ongoing research reimbursements, milestone conditions and the assumptions behind the mid-2023 cash runway estimate.
- Track cash burn, financing needs and dilution, including the effect of share-based awards and future equity issuance.
- Confirm Shannon facility completion, regulatory readiness, manufacturing yields and plasmid supply independence.
- Review subsequent clinical updates for AAV-AQP1 and achromatopsia programs, including patient numbers, durability and adverse events.